Methods are described for measuring plasminogen levels in human plasma and for studying plasmin generation in plasma with plasminogen activators. In plasma samples from two individuals with histories of deep vein thrombosis, the functional plasminogen values were determined to be below the normal range of 16.7 to 23.8 mg/lOO ml (average of 21.0 mg/lOO ml), and the plasmin generation rates were ...

The aim of this research is to evaluate the current streptokinase thrombolytic treatment and to identify or improve new techniques that will base new approaches with a higher efficiency in this area of expertise. In order to be as realistic as possible a new method was set up using magnetic vectorized nanoparticles streptokinase and human blood thrombus. The experimental data confirm the maximu...

The aim of thrombolytic therapy for acute myocardial infarction with plasminogen activators such as streptokinase is to lyse the coronary thrombus and reestablish blood flow as quickly as possible so that heart tissue loss is minimized and mortality rates are improved. Streptokinase has been encapsulated in large unilamellar phospholipid vesicles and tested in an animal model of acute myocardia...

Streptococcus pyogenes is commonly believed to be resistant to trimethoprim-sulfamethoxazole (SXT), resulting in reservations about using SXT for skin and soft tissue infections (SSTI) where S. pyogenes is involved. S. pyogenes' in vitro susceptibility to SXT depends on the medium's thymidine content. Thymidine allows S. pyogenes to bypass the sulfur-mediated inhibition of folate metabolism and...

Plasminogen, a normal constituent of human blood plasma, can be activated in various ways to yield the proteolytic enzyme plasmin capable of dissolving fibrin clots and of hydrolyzing a variety of other proteins and synthetic amino acid esters. The activation by the bacterial product streptokinase has been widely studied in the past and appears to proceed through a two-stage reaction: the inter...

Plasma exchange and intravenous immunoglobulin are effective in treating Guillain-Barré syndrome (GBS) probably because the former removes IgG autoantibodies and complement and the latter inhibits complement activation subsequent to the autoantibody binding to peripheral nerve antigens. IgG degrading enzyme of Streptococcus pyogenes (IdeS) can cleave the pathogenic autoantibodies into F(ab')2 a...

A failure of hemostasis and consequent formation of blood clots in the circulatory system can produce severe outcomes such as stroke and myocardial infraction. Pathological development of blood clots requires clinical intervention with fibrinolytic agents such as urokinase, tissue plasminogen activator and streptokinase. This review deals with streptokinase as a clinically important and cost-ef...

Clinically encouraging results can be obtained with an intravenous high dosage, short-term infusion of streptokinase in patients with evolving myocardial infarction. The feasibility and efficacy of the systemic approach of streptokinase therapy is discussed in this report and includes topics such as recanalization success rate, restoration of coronary blood flow, residual coronary artery lesion...

B. ROBERTSON, INGA MARIE NILSSON, AND G. NYLANDER (Department of Surgery, Coagulation Laboratory, and the Department of Roentgenology, University of Lund, Malmo, Sweden Three coded series of patients, 50 in all, with acute deep venous leg thrombosis of at most 96 hours' duration were treated with streptokinase (Kabikinase(R), Kabi) or heparin by intravenous drip (Table I) followed by subcutaneo...

An overview of eight randomized controlled trials of tissue-type plasminogen activator (Alteplase or Duteplase) and 10 of anisoylated plasminogen streptokinase activator complex (Anistreplase) showed that the odds of early death were reduced by 29% by tissue-type plasminogen activator and 46% by anisoylated plasminogen streptokinase activator complex, with overlapping 95% confidence intervals. ...